Neprilysin inhibitors
US-9845332-B2 · Dec 19, 2017 · US
Neprilysin inhibitors
US10336773B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10336773-B2 |
| Application number | US-201715806680-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 8, 2017 |
| Priority date | Dec 15, 2010 |
| Publication date | Jul 2, 2019 |
| Grant date | Jul 2, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. (2R,4R)-5-Biphenyl-4-yl-4-[(5-carboxymethyl-1H-pyrazole-3-carbonyl)amino]-2-hydroxy-pentanoic acid or a pharmaceutically acceptable salt thereof. 2. (2R,4R)-5-Biphenyl-4-yl-2-hydroxy-4-[(5-hydroxymethyl-1H-pyrazole-3-carbonyl)-amino]-pentanoic acid or a pharmaceutically acceptable salt thereof. 3. (2R,4R)-5-Biphenyl-4-yl-2-hydroxy-4-[(5-methoxymethyl-1H-pyrazole-3-carbonyl)-amino]-pentanoic acid or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising the compound of any one of claims 1 - 3 and a pharmaceutically acceptable carrier. 5. The pharmaceutical composition of claim 4 , further comprising an AT 1 receptor antagonist. 6. A method for therapeutically treating hypertension, heart failure, or renal disease, comprising administering to a patient a therapeutically effective amount of the compound of any one of claims 1 - 3 .
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antihypertensives · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antioedematous agents; Diuretics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10336773B2 cover?
- In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; an…
- Who is the assignee on this patent?
- Theravance Biopharma R&D Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D213/81. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).